PMID- 28557861 OWN - NLM STAT- MEDLINE DCOM- 20180518 LR - 20181202 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) VI - 63 IP - 6 DP - 2017 Nov/Dec TI - HeartMate 3 in Lowest INTERMACS Profile Cohort: The Swiss Experience. PG - 752-758 LID - 10.1097/MAT.0000000000000589 [doi] AB - New generation devices for long-term mechanical circulatory support are centrifugal pumps having fully magnetically levitated rotors to reduce blood trauma. Recently, the novel HeartMate 3 was cleared for clinical application in Switzerland. In two Swiss University Hospitals part of the "Lausanne-Geneva Transplantation Network," 10 consecutive patients in end-stage heart failure received the HeartMate 3 (Thoratec Corporation, Pleasanton, CA). Device implantation criteria were persistent low output syndrome despite optimal medical treatment. The primary end-point of the study was survival or transplantation to 90 days on the device. Five patients (50%) were in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) class 1 and 2 (two were under venoarterial extracorporeal membrane oxygenation [VA-ECMO]), and five were in class 3 and 4. The indication was bridge-to-transplant in seven patients, and destination therapy in three. Two patients (20%) received concomitant aortic valve surgery. Four patients (40%) required temporary right ventricle support (tRVAD) for a mean of 8 +/- 1.5 days. Bleeding requiring surgical revision occurred in five (50%) patients, two during the tRVAD support. At the 90 day end-point, survival was 90%, one (10%) died due to respiratory failure. Three (30%) experienced critical illness polyneuropathy. Two had body temperature over 38.5 degrees C for more than 7 days after implant, without infections. Two (20%) had late driveline infection. The pump allowed rapid improvement of patients' clinical conditions even in severely compromised patients. Postoperative bleeding occurred in the setting of anticoagulation. No hemolysis or pump thrombosis occurred. Fever occurred frequently but was not associated with mortality. Hemodynamic support was consistent over time without significant adverse events. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - From the *Department of Cardiac Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; daggerDepartment of Cardiovascular Surgery, Hopitaux Universitaires de Geneve (HUG), Geneva, Switzerland; double daggerDepartment of Cardiology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; section signDepartment of Cardiology, Hopitaux Universitaires de Geneve (HUG), Geneve, Switzerland; paragraph signDepartment of Intensive Care Unit, Hopitaux Universitaires de Geneve (HUG), Geneva, Switzerland; ||Department of Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; and #Department of Anesthesiology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. FAU - Banfi, Carlo AU - Banfi C FAU - Ahmadov, Kameran AU - Ahmadov K FAU - Hullin, Roger AU - Hullin R FAU - Meyer, Philippe AU - Meyer P FAU - Giraud, Raphael AU - Giraud R FAU - Liaudet, Lucas AU - Liaudet L FAU - Gronchi, Fabrizio AU - Gronchi F FAU - Huber, Christophe AU - Huber C FAU - Kirsch, Matthias AU - Kirsch M LA - eng PT - Journal Article PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM MH - Adult MH - Aged MH - Female MH - Heart Failure/mortality/therapy MH - Heart Transplantation MH - Heart-Assist Devices/*adverse effects MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Registries EDAT- 2017/05/31 06:00 MHDA- 2018/05/19 06:00 CRDT- 2017/05/31 06:00 PHST- 2017/05/31 06:00 [pubmed] PHST- 2018/05/19 06:00 [medline] PHST- 2017/05/31 06:00 [entrez] AID - 10.1097/MAT.0000000000000589 [doi] PST - ppublish SO - ASAIO J. 2017 Nov/Dec;63(6):752-758. doi: 10.1097/MAT.0000000000000589.